Sildenafil for chronic obstructive pulmonary disease: A randomized crossover trial

COPD: Journal of Chronic Obstructive Pulmonary Disease

Volumn 9, Issue 3, 2012, Pages 268-275

  Lederer, David J ^a   Bartels, Matthew N ^b   Schluger, Neil W ^a   Brogan, Frances ^c   Jellen, Patricia ^c   Thomashow, Byron M ^a   Kawut, Steven M ^d  

^a Columbia University ^*  (United States)

^b New York Presbyterian Hospital ^*  (United States)

^c NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Clinical Trial; COPD; Emphysema; Pulmonary hypertension.; Sildenafil

Indexed keywords

CARBON MONOXIDE; PLACEBO; SILDENAFIL;

ABDOMINAL PAIN; ADULT; ARTICLE; BLURRED VISION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; EMPHYSEMA; EXERCISE; FORCED EXPIRATORY VOLUME; HUMAN; LUNG ALVEOLUS OXYGEN TENSION; OXYGEN CONSUMPTION; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SYMPTOM; WALKING;

AGED; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; EXERCISE TEST; FEMALE; HUMANS; HYPERTENSION, PULMONARY; MALE; MIDDLE AGED; OXYGEN CONSUMPTION; PIPERAZINES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; PURINES; QUALITY OF LIFE; SULFONES; TREATMENT OUTCOME; VASODILATOR AGENTS;

EID: 84862087261     PISSN: 15412555     EISSN: 15412563     Source Type: Journal    
DOI: 10.3109/15412555.2011.651180     Document Type: Article

References (22)

1. O'Donnell DE, Banzett RB, Carrieri-Kohlman V, Casaburi R, Davenport PW, Gandevia SC, Gelb AF, Mahler DA, Webb KA. Pathophysiology of dyspnea in chronic obstructive pulmonary disease: A roundtable. Proc Am Thorac Soc 2007 May; 4(2):145-168.
2. Vonk-Noordegraaf A, Marcus JT, Holverda S, Roseboom B, Postmus PE. Early changes of cardiac structure and function in copd patients with mild hypoxemia. Chest 2005 Jun; 127(6):1898-1903.
3. Kessler R, Faller M, Weitzenblum E, Chaouat A, Aykut A, Ducolone A, Ehrhart M, Oswald-Mammosser M. "Natural history" of pulmonary hypertension in a series of 131 patients with chronic obstructive lung disease. Am J Respir Crit Care Med 2001 Jul 15; 164(2):219-224.
4. Holverda S, Rietema H, Westerhof N, Marcus JT, Gan CT, Postmus PE, Vonk-Noordegraaf A. Stroke volume increase to exercise in chronic obstructive pulmonary disease is limited by increased pulmonary artery pressure. Heart 2009 Feb; 95(2):137-141.
5. Nocturnal Oxygen Therapy Trial Group. Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: A clinical trial. Ann Intern Med 1980 Sep; 93(3):391-398.
6. Report of the Medical Research Council Working Party. Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Lancet 1981 Mar 28; 1(8222):681-686.
7. Vestri R, Philip-Joet F, Surpas P, Arnaud A, Saadjian A. Oneyear clinical study on nifedipine in the treatment of pulmonary hypertension in chronic obstructive lung disease. Respiration 1988; 54(2):139-144.
8. Stolz D, Rasch H, Linka A, Di Valentino M, Meyer A, Brutsche M, Tamm M. A randomised, controlled trial of bosentan in severe copd. Eur Respir J 2008 Sep; 32(3):619-628.
9. Kalra L, Bone MF. Effect of nifedipine on physiologic shunting and oxygenation in chronic obstructive pulmonary disease. Am J Med 1993 Apr; 94(4):419-423.
10. Ghofrani HA, Wiedemann R, Rose F, Schermuly RT, Olschewski H, Weissmann N, Gunther A, Walmrath D, Seeger W, Grimminger F. Sildenafi l for treatment of lung fi brosis and pulmonary hypertension: A randomised controlled trial. Lancet 2002 Sep 21; 360(9337):895-900.
11. Nagendran J, Archer SL, Soliman D, Gurtu V, Moudgil R, Haromy A, St Aubin C, Webster L, Rebeyka IM, Ross DB, Light PE, Dyck JR, Michelakis ED. Phosphodiesterase type 5 is highly expressed in the hypertrophied human right ventricle, and acute inhibition of phosphodiesterase type 5 improves contractility. Circulation 2007 Jul 17; 116(3):238-248.
12. Holverda S, Rietema H, Bogaard HJ, Westerhof N, Postmus PE, Boonstra A, Vonk-Noordegraaf A. Acute eff ects of sildenafi l on exercise pulmonary hemodynamics and capacity in patients with copd. Pulm Pharmacol Ther 2008; 21(3):558-564.
13. Blanco I, Gimeno E, Munoz PA, Pizarro S, Gistau C, Rodriguez-Roisin R, Roca J, Barbera JA. Hemodynamic and gas exchange eff ects of sildenafi l in patients with chronic obstructive pulmonary disease and pulmonary hypertension. Am J Respir Crit Care Med 2010 Feb 1; 181(3):270-278.
14. Vonbank K, Ziesche R, Higenbottam TW, Stiebellehner L, Petkov V, Schenk P, Germann P, Block LH. Controlled prospective randomised trial on the eff ects on pulmonary haemodynamics of the ambulatory long term use of nitric oxide and oxygen in patients with severe copd. Th orax 2003 Apr; 58(4):289-293.
15. Galie N, Ghofrani HA, Torbicki A, Barst RJ, Rubin LJ, Badesch D, Fleming T, Parpia T, Burgess G, Branzi A, Grimminger F, Kurzyna M, Simonneau G. Sildenafi l Use in Pulmonary Arterial Hypertension Study G. Sildenafi l citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005 Nov 17; 353(20):2148-2157.
16. Simonneau G, Rubin LJ, Galie N, Barst RJ, Fleming TR, Frost AE, Engel PJ, Kramer MR, Burgess G, Collings L, Cossons N, Sitbon O, Badesch DB, Group PS. Addition of sildenafi l to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: A randomized trial. Ann Intern Med 2008 Oct 21; 149(8):521-530.
17. Idiopathic Pulmonary Fibrosis Clinical Research, Zisman DA, Schwarz M, Anstrom KJ, Collard HR, Flaherty KR, Hunninghake GW. A controlled trial of sildenafi l in advanced idiopathic pulmonary fi brosis. N Engl J Med 2010 Aug 12; 363(7):620-628.
18. Alp S, Skrygan M, Schmidt WE, Bastian A. Sildenafi l improves hemodynamic parameters in copd-An investigation of six patients. Pulm Pharmacol Ther 2006; 19(6):386-390.
19. Rietema H, Holverda S, Bogaard HJ, Marcus JT, Smit HJ, Westerhof N, Postmus PE, Boonstra A, Vonk-Noordegraaf A. Sildenafi l treatment in copd does not aff ect stroke volume or exercise capacity. Eur Respir J 2008 Apr; 31(4):759-764.
20. Wyrwich KW, Tierney WM, Babu AN, Kroenke K, Wolinsky FD. A comparison of clinically important diff erences in health-related quality of life for patients with chronic lung disease, asthma, or heart disease. Health Serv Res 2005 Apr; 40(2):577-591.
21. Redelmeier DA, Guyatt GH, Goldstein RS. Assessing the minimal important diff erence in symptoms: A comparison of two techniques. J Clin Epidemiol 1996 Nov; 49(11):1215-1219.
22. Jones PW. Quality of life, symptoms and pulmonary function in asthma: Long-term treatment with nedocromil sodium examined in a controlled multicentre trial. Nedocromil Sodium Quality of Life Study Group. Eur Respir J 1994 Jan; 7(1):55-62.